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Abstract
Vitiligo is an autoimmune disease in which depigmented skin results from destruction of 
melanocytes1, with epidemiologic association with other autoimmune diseases2. In previous 
linkage and genome-wide association studies (GWAS1, GWAS2), we identified 27 vitiligo 
susceptibility loci in patients of European (EUR) ancestry. We carried out a third GWAS (GWAS3) 
in EUR subjects, with augmented GWAS1 and GWAS2 controls, genome-wide imputation, and 
meta-analysis of all three GWAS, followed by an independent replication. The combined analyses, 
with 4,680 cases and 39,586 controls, identified 23 new loci and 7 suggestive loci, most encoding 
immune and apoptotic regulators, some also associated with other autoimmune diseases, as well as 
several melanocyte regulators. Bioinformatic analyses indicate a predominance of causal 
regulatory variation, some corresponding to eQTL at these loci. Together, the identified genes 
provide a framework for vitiligo genetic architecture and pathobiology, highlight relationships to 
other autoimmune diseases and melanoma, and offer potential targets for treatment.
In previous genome-wide linkage and association studies, we identified 27 vitiligo 
susceptibility loci3–6 in EUR subjects, principally encoding immunoregulatory proteins, 
many of which are associated with other autoimmune diseases7. Several other vitiligo-
associated genes encode melanocyte components that regulate normal pigmentary variation8 
and in some cases are major vitiligo autoimmune antigens, with an inverse association of 
variation at these loci with vitiligo versus malignant melanoma4,6. To detect additional 
vitiligo-associations with lower odds ratios (ORs), as well as uncommon risk alleles with 
higher ORs, we conducted a third GWAS (GWAS3) of EUR subjects. We augmented the 
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number of population controls in our previous GWAS1 and GWAS2 and performed genome-
wide imputation of all three EUR vitiligo GWAS. After quality control procedures, the 
augmented studies included 1,381 cases and 14,518 controls (GWAS1), 413 cases and 5,209 
controls (GWAS2), and 1,059 cases and 17,678 controls (GWAS3), with genomic inflation 
factors 1.068, 1.059, and 1.013, respectively. We performed a fixed-effects meta-analysis of 
the three GWAS datasets for 8,966,411 markers (GWAS123; Online Methods). Replication 
used an additional 1,827 EUR vitiligo cases and 2,181 controls.
Results for the three individual GWAS, the meta-analysis, and the replication study are 
presented in Table 1, Supplementary Table 1, and Fig. 1. Twenty-three new loci achieved 
genome-wide significance (P < 5 × 10−8) for association with vitiligo and demonstrated 
subsequent replication; of these, 21 are completely novel (FASLG, PTPRC, PPP4R3B, 
BCL2L11, FARP2-STK25, UBE2E2, FBXO45-NRROS, PPP3CA, IRF4, SERPINB9, 
CPVL, NEK6, ARID5B, a multigenic segment that includes BAD, TNFSF11, KAT2A-
HSPB9-RAB5C, TNFRSF11A, SCAF1-IRF3-BCL2L12, a multigenic segment that includes 
ASIP, PTPN1, and IL1RAPL1), while two, CTLA4 and TICAM1, were suggestive in our 
previous studies. One previously significant locus, CLNK, was no longer significant 
(Supplementary Table 1). Another potential new locus, PVT1, exceeded genome-wide 
significance in the discovery meta-analysis (P = 7.74 × 10−9), but could not be successfully 
genotyped in the replication study and so remains uncertain. Two other loci, FLI1 and 
LOC101060498, exceeded genome-wide significance in the discovery meta-analysis (P = 
3.76 × 10−8 and P = 3.60 × 10−11, respectively), but did not demonstrate replication. Seven 
additional novel loci achieved suggestive significance (P < 10−5) in the discovery meta-
analysis (STAT4, PPARGC1B, c7orf72, PARP12, FADS2, CBFA2T3, and a chr17 locus in 
the vicinity of AFMID) and gave evidence of replication, but failed to achieve genome-wide 
significance (Supplementary Table 1).
Together, the most significantly associated variants at the 48 loci (Table 1) identified by 
meta-analyses of the three GWAS account for 17.4% of vitiligo heritability (h2 ~ 0.75). To 
assess whether additional independent variants at these loci might account for additional 
vitiligo heritability, we performed logistic regression conditional on the most significant 
SNP at each locus. Eight loci (FARP2-STK25, IFIH1, IL2RA, LPP, MC1R, SLA/TG, TYR, 
UBASH3A) and the MHC showed evidence of additional independent associations, 
accounting for an additional 5.1% of vitiligo heritability, for a total of 22.5%. In general, the 
ORs for the 23 new confirmed loci were lower than those for loci detected previously6, 1.15 
to 1.27, excepting CPVL (OR = 1.84), RALY-EIF252-ASIP-AHCY-ITCH (OR = 1.64), and 
IL1RAPL1 (OR = 1.77); for these three signals the associated alleles are uncommon (minor 
allele frequencies 0.03, 0.07, and 0.01, respectively) and thus were not detected in the 
previous GWAS due to power limitations.
To screen for functional relationships among proteins encoded at the 48 confirmed vitiligo-
associated loci, we included all genes under the association peaks at these loci in 
unsupervised pathway analyses using g:PROFILER9, PANTHER10, and STRING11. 
PANTHER and gPROFILER identified an enriched network of BioGRID interactions, most 
significant for the GO categories immune response, immune system process, positive 
regulation of response to stimulus, positive regulation of biological process, and regulation 
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of response to stimulus. STRING identified a large potential interaction network (Fig. 2), 
with a predominance of proteins involved in immunoregulation, T-cell receptor repertoire, 
apoptosis, antigen processing and presentation, and melanocyte function.
Considering proteins encoded at the 23 newly confirmed vitiligo candidate loci, at least 
twelve (CTLA4, TICAM1, PTPRC, FARP2, UBE2E2, NRROS, CPVL, ARID5B, PTPN1, 
TNFSF11, TNFRSF11A, IRF3, and perhaps also IL1RAPL1) play roles in immune 
regulation, and PPP3CA may regulate FOXP3 via NFATC2 and is associated with canine 
lupus12. Six (FASLG, BCL2L11, BCL2L12, SERPINB9, NEK6, BAD) are regulators of 
apoptosis, particularly involving immune cells. ASIP is a regulator of melanocyte gene 
expression, and IRF4 is a key transcription factor for both immune cells and melanocytes.
Strikingly, several vitiligo-associated genes encode proteins that interact physically and 
functionally. BCL2L11 and BAD are binding partners that promote apoptosis13. CD80 binds 
to CTLA4 to inhibit T cell activation14. BCL2L12 binds to and neutralizes caspase 7 
(CASP7)15. SERPINB9 binds to and specifically inhibits granzyme B (GZMB)16. Eos 
(IKZF4) binds and is an obligatory co-repressor of FOXP3 in regulatory T cells17. RANK 
(TNFRSF11A) binds to RANKL (TNFSF11) to regulate many aspects of immune cell 
function, including interactions of T cells and dendritic cells and thymic tolerization18. 
Agouti signaling protein (ASIP) binds to the melanocortin-1 receptor (MC1R) to down-
regulate production of brown-black eumelanin19. IRF4 cooperates with MITF to activate 
transcription of TYR20. And the vitiligo-associated HLA-A*02:01:01:01 subtype presents 
peptide antigens derived from several different melanocyte proteins, including tyrosinase 
(TYR), OCA2, and MC1R4,6,21. Together, these relationships appear to highlight key 
pathways of vitiligo pathogenesis that are beginning to coalesce.
An unexpected finding from vitiligo GWAS has been an inverse relationship between 
vitiligo and malignant melanoma risk for genes that encode melanocyte structural and 
regulatory proteins. TYR, OCA2, and MC1R, encode functional components of the 
melanocyte and are key vitiligo autoantigens. IRF4 encodes a transcription factor for 
melanocytes as well as lymphoid, myeloid, and dendritic cells22, controlled by alternative 
tissue-specific enhancers23. ASIP and PPARGC1B encode paracrine regulators of 
melanocyte gene expression. All six loci play important roles in normal pigmentary 
variation8,24, and for all six the specific SNPs associated with vitiligo risk are also 
associated with melanoma protection, and vice-versa25–27. The inverse genetic relationship 
of susceptibility to vitiligo versus melanoma suggests that vitiligo may represent enhanced 
immune surveillance against melanoma27,28, consistent with the threefold reduction in 
melanoma incidence among vitiligo patients29,30 and prolonged survival of melanoma 
patients who develop vitiligo during immunotherapy31.
Vitiligo is epidemiologically associated with several other autoimmune diseases, including 
autoimmune thyroid disease, pernicious anemia, rheumatoid arthritis, adult-onset type 1 
diabetes, Addison’s disease, and lupus2,32. We searched the NHGRI-EBI GWAS Catalog 
and PubMed for the 48 genome-wide significant and 7 suggestive vitiligo susceptibility loci 
for associations with other autoimmune, inflammatory, and immune-related disorders. As 
shown in Fig. 3, of the 23 novel genome-wide significant vitiligo loci, FASLG has been 
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associated with celiac disease33 and Crohn’s disease34; PTPRC with ulcerative colitis35; 
BCL2L11 with primary sclerosing cholangitis36; CTLA4 with alopecia areata37, rheumatoid 
arthritis38, autoimmune thyroid disease39,40, myasthenia gravis41, and type 1 diabetes 
autoantibody production42; TNFRSF11A with myasthenia gravis41; and ARID5B with 
systemic lupus erythematosus43. Of the seven suggestive loci, STAT4 has been associated 
with Behḉet’s disease44, Sjögren’s syndrome45, and lupus46; and c7orf72 with lupus47. 
These concordant associations for vitiligo and other autoimmune and inflammatory diseases 
add to those involving previously identified vitiligo susceptibility loci, which include RERE, 
PTPN22, IFIH1, CD80, LPP, BACH2, RNASET2-FGFR1OP-CCR6, TG/SLA, IL2RA, 
CD44, a chr11q21 gene desert, IKZF4, SH2B3-ATXN2, UBASH3A, and C1QTNF64,6. 
Nevertheless, in most cases it remains uncertain whether apparent shared locus associations 
for different autoimmune diseases reflect shared or different underlying causal variants.
A majority of loci associated with complex traits involve causal variants that are regulatory 
in nature48–52, often corresponding to apparent expression quantitative trait loci (eQTLs)52. 
For TYR21, GZMB53, and MC1R7, principal vitiligo risk derives from missense 
substitutions, whereas for OCA26 and the MHC class I54 and class II55 loci principal vitiligo 
risk is associated with causal variation in nearby transcriptional regulatory elements. To 
assess the fraction of vitiligo-associated loci for which causal variation is likely regulatory, 
we carried out conditional logistic regression analysis of all loci to define independent 
association signals, and for each signal we compiled all variants that could not be 
statistically distinguished. All variants were then annotated against all available ENCODE 
datasets for immune-related and melanocyte-related cells (Supplementary Table 2). Overall, 
at approximately 58% of loci, the most significant variants (or statistically indistinguishable 
variants) are within a transcriptional regulatory element predicted by ENCODE data56,57. 
Only about 15% are in coding regions, several resulting in missense substitutions. To further 
assess the general functional categories of apparent causal variants for vitiligo, we applied 
stratified LD score regression51 to the GWAS meta-analysis summary statistics. As shown in 
Fig. 4, greatest enrichment of heritability was observed for markers in regulatory functional 
categories, with considerably less enrichment of markers in protein coding regions.
We utilized two approaches to assess correspondence of vitiligo association signals with 
expression of genes in the vicinity. We used PrediXcan58 to predict expression of 11,553 
genes in whole blood for each study subject and then tested association of predicted 
expression of each gene with vitiligo affection status. We used a Bayesian method to assess 
co-localization of cis eQTL signals in purified blood monocytes with the confirmed vitiligo 
association signals. The PrediXcan analysis found 83 genes with significant differential 
predicted expression in vitiligo cases versus controls after Bonferroni correction 
(Supplementary Table 3); of these, 75 were located within 1 Mb of one of the 48 confirmed 
vitiligo susceptibility loci, demonstrating highly significant enrichment compared with 
locations of genes non-significant for PrediXcan (P value < 0.00001). The eQTL analysis 
found that 8 of the confirmed vitiligo association signals showed significant co-localization 
with eQTL association signals identified in purified monocytes (Supplementary Fig. 1 and 
Supplementary Table 4). Of the confirmed vitiligo-associated genes that could be tested 
using both methods, 6 were significant in both analyses (CASP7, HERC2-OCA2, ZC3H7B-
TEF, TICAM1, RERE, RNASET2-FGFR1OP-CCR6). For all of these except CASP7, one 
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or more of the most associated SNPs not distinguishable by logistic regression was located 
within or very close to an ENCODE element likely to regulate gene expression in immune 
cell types, melanocytes, or both (Supplementary Table 2).
Like a jigsaw puzzle, the pieces of the vitiligo pathogenome are thus beginning to fit 
together, revealing a complex network of immunoregulatory proteins, apoptotic regulators, 
and melanocyte components that mediate both autoimmune targeting of melanocytes in 
vitiligo and susceptibility to melanoma. For vitiligo as for other complex diseases, there is 
enrichment of causal variation in regions that regulate gene expression. This may bode well 
for identifying potential therapeutic targets, as pharmacologic modulation of dysregulated 
biological pathways may prove more tractable than attempting to target proteins impacted by 
amino acid substitutions.
ONLINE METHODS
Subjects
The genome-wide portion of this study included unrelated cases from our three generalized 
vitiligo GWAS: GWAS14 (n = 1514), GWAS26 (n = 450), and the current GWAS3 (n = 
1090). All cases were of non-Hispanic-Latino European-derived white ancestry (EUR) from 
North America and Europe, and met strict clinical criteria for generalized vitiligo59. All 
controls were EUR individuals not specifically known to have any autoimmune disease or 
malignant melanoma, for whom genome-wide genotypes were obtained from the NCBI 
database of Genotypes and Phenotypes (dbGaP; phs000092.v1.p1, phs000125.v1.p1, 
phs000138.v2.p1, phs000142.v1.p1, phs000168.v1.p1, phs000169.v1.p1, phs000206.v3.p2, 
phs000237.v1.p1, phs000346.v1.p1, and phs000439.v1.p1 for GWAS1; phs000203.v1.p1, 
and phs000289.v2.p1 for GWAS2; phs000196.v2.p1, phs000303.v1.p1, phs000304.v1.p1, 
phs000368.v1.p1, phs000381.v1.p1, phs000387.v1.p1, phs000389.v1.p1, phs000395.v1.p1, 
phs000408.v1.p1, phs000421.v1.p1, phs000494.v1.p1, and phs000524.v1.p1 for GWAS3). 
Control datasets were matched to each of the three GWAS case datasets based on platforms 
used for genotyping. The independent replication study included 1827 unrelated EUR 
vitiligo cases and 2181 unrelated EUR controls not included in any of the GWAS. All 
subjects provided written informed consent. This study was carried out under the jurisdiction 
of each local IRB with overall oversight of the Colorado Multiple Institutional Review 
Board (COMIRB).
Genome-wide genotyping
Saliva specimens were obtained using a DNA self-collection kit (Oragene, DNA Genotek), 
and DNA was prepared using either the Maxwell apparatus/16 LEV Blood DNA kit 
(Promega) or the DNA Genotek Oragene Purifier protocol. DNA concentrations were 
measured using either the Qubit dsDNA BR Assay kit and Qubit 2.0 Fluorometer 
(Invitrogen) or the Promega QuantiFluor ONE dsDNA kit and GloMax®-Multi+ Detection 
System (Promega).
Genome-wide genotyping for the GWAS3 cases was performed for 716,503 variants using 
Illumina Human OmniExpress BeadChips by the Center for Inherited Disease Research 
Jin et al. Page 6
Nat Genet. Author manuscript; available in PMC 2017 April 10.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
(CIDR). Genotype data for GWAS3 were deposited in dbGaP (phs000224.v3.p1). GWAS14 
and GWAS26 have been described previously.
Genome-wide quality control procedures
Quality control filtering of genome-wide genotype data was carried out using PLINK60, 
version 1.9. For each case/control dataset, DNA strand calls were reversed as needed. Cases 
were excluded on the basis of SNP call rates <98.5%, discordance between reported and 
observed sex, or inadvertent subject duplication, and controls were excluded on the basis of 
SNP call rates < 98%. SNPs were excluded on the basis of genotype missing rate > 2% for 
SNPs with observed minor allele frequency (MAF) ≥ 0.01, and for SNPs with MAF < 0.01 
exclusion criteria were genotype missing rate >1% and < 5 minor alleles observed, or 
significant (P < 10−4) deviation from Hardy-Weinberg equilibrium. For X chromosome 
SNPs, Hardy-Weinberg equilibrium tests were performed in females, and SNPs with P < 
10−4 were excluded from the final analysis. For each GWAS, only SNPs that existed in all 
case and control datasets were retained for imputation.
Within each GWAS, subjects were excluded based on cryptic relatedness identified by 
pairwise identity-by-descent estimations (pi-hat > 0.0625), in which case the individual with 
lower SNP call rate was excluded. For each of the three GWAS, the cleaned case dataset was 
combined with one cleaned control dataset at a time and the genotype data of 270 subjects of 
Phase I and II of the International HapMap Project from 4 populations, and principal 
components analysis (PCA) was performed with EIGENSOFT59 based on tag-SNPs (within 
which no pair were correlated with r2 >0.2) selected from genotyped SNPs. The first two 
eigenvectors were used to produce a PCA plot. A PCA plot was first made for cases and 
HapMap samples, and cases that were clearly separated from the main cluster of cases and 
HapMap EUR samples were excluded as outliers. A PCA plot of controls and HapMap 
samples was then made, and the same x and y coordinates that separated the case outliers 
from the main cluster of cases and HapMap EUR samples were used to identify control 
outliers.
After all QC procedures, the final number of genotyped SNPs remaining in GWAS1, 
GWAS2, and GWAS3 were 464,902, 494,043, and 483,609, respectively. For autosomal 
analyses, the final numbers of cases and controls in GWAS1, GWAS2, and GWAS3 were 
1,381 and 14,518, 413 and 5,209, and 1,059 and 17,678, respectively, whereas for X 
chromosome analyses, the final numbers of cases and controls in GWAS1, GWAS2, and 
GWAS3 were 1,380 and 9,439, 413 and 5,209, and 1,059 and 14,220, respectively. This 
sample size provided at least 85% power to detect associations with OR ≥ 1.22 at genome-
wide significance (P = 5 × 10−8) for MAF ≥ 0.25.
Genome-wide Genotype Imputation
For each GWAS, we used SHAPEIT version2 to pre-phase genotypes to produce best-guess 
haplotypes, and then performed imputation with these estimated haplotypes using IMPUTE2 
and the 1000 Genomes Project phase I integrated variant set version 3 (March, 2012) as the 
reference panel. All cryptic related individuals and outliers from each GWAS were included 
in the process to improve imputation accuracy, but were removed for the final analyses. Only 
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genotypes with imputation INFO ≥ 0.5 were retained, which were combined with prior SNP 
genotype data. Imputed genotypes for variants with MAF ≥ 0.01 calculated from all 3 
GWAS combined and without significant (P > 10−5) deviation from Hardy-Weinberg 
equilibrium were used in the final analysis, which included 8,721,242 autosome variants and 
245,169 chromosome X variants.
Replication study genotyping and quality control procedures
For the replication study, genotyping was attempted for 379 variants using a custom Illumina 
Golden Gate array by CIDR. 71 SNPs were excluded on the basis of genotype missing rate > 
2% (which includes apparent technical failures), or significant (P < 10−4) deviation from 
Hardy-Weinberg equilibrium. For X chromosome SNPs, Hardy-Weinberg equilibrium tests 
were performed in females. Subjects were excluded on the basis of SNP call rates <95%, or 
discordance between reported and observed sex. Unintended duplicate samples were 
identified by pairwise identity-by-descent estimations (pi-hat > 0.99), in which case the 
individual with lower SNP call rate was excluded. The final numbers of remaining cases and 
controls were 1,827 and 2,181, respectively, providing at least 80% power to replicate 
associations at P = 0.05 with Bonferroni correction for up to 48 independent tests for OR ≥ 
1.23 for MAF ≥ 0.25.
Statistical analyses
To control for the effects of population stratification, we assigned cases and controls of each 
GWAS to homogenous clusters using GemTools60, and performed Cochran-Mantel- 
Haenszel (CMH) analysis to test for association for each GWAS and the combined GWAS 
data, with the cluster variable defined by the case-control clusters from each GWAS. After 
removing variants within the extended MHC, the genomic inflation factor for GWAS1, 
GWAS2, and GWAS3 was 1.068, 1.059, and 1.013, respectively. For the combined GWAS1–
GWAS2–GWAS3 genotype data for shared SNPs, the genomic inflation factor was 1.019.
For the replication study, after quality control procedures we compared allele frequencies for 
the remaining 308 SNPs in the remaining 1,827 cases and 2,181 controls using the Cochran-
Armitage trend test. ORs and 95% confidence limits were calculated by logistic regression 
analysis. We used CMH analysis to obtain ORs and P values for the combined GWAS plus 
the replication study data, with the cluster variable defined by the case-control clusters from 
each GWAS and the replication study data as one cluster. To analyze X chromosome SNPs, 
we assumed complete X-inactivation and similar effect size between males and females, 
with the effect of having an A allele in a male equal to the effect of having two A alleles in a 
female63. We thus coded males as homozygous for the allele carried for each variant and 
tested for association by CMH analysis to obtain ORs and P values for each GWAS, the 
combined GWAS, and the combined GWAS plus the replication study data, and by the 
Cochran- Armitage trend test for the replication study data.
To test heterogeneity of associations across the three GWAS and the replication study data, 
we performed the Cochran Q test. The analysis was done with PLINK, version 1.07, using 
the ORs and standard errors estimated from the CMH analysis of each GWAS, and from 
logistic regression analysis of the replication study data. The I2 statistic from the Q test 
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quantifies heterogeneity and ranges from 0% to 100%64, with a value of 75% or greater 
typically taken to indicate a high degree of heterogeneity65.
To test for multiple independent signals at each locus, we performed logistic regression 
analysis of each locus conditional on the most significantly associated variant, including as 
covariates in the model the significant principal components for each GWAS derived from 
GemTools62 to control for population stratification, and used a stepwise procedure to select 
additional variants, one by one, until no additional variants showed conditional P values ≤ 
1.0 × 10−5. If a tested variant and the conditional variant could not improve each other 
significantly (P ≥ 0.05 when comparing the two SNP model to a single SNP model), then 
both variants were considered to represent the same signal. We calculated the variance 
explained by a specific variant or a set of variants from the combined GWAS as the Pseudo 
R2 of a logistic regression model which included the specific variants tested.
Bioinformatic pathway and functional enrichment analyses
To screen for functional relationships among the vitiligo candidate genes, we carried out 
pathway analysis of the protein products of all positional candidate genes at all 48 confirmed 
loci and the seven suggestive loci using g:PROFILER10, PANTHER11, and STRING12. To 
assess enrichment of association signals in different functional genomic categories 
contributing to vitiligo heritability, we applied stratified LD score regression51 to the 
combined CMH GWAS123 summary statistics. The regression model contained 24 
overlapping functional categories, including coding, UTR, promoter and intronic regions, 
annotations for different histone marks, DNase I hypersensitivity site (DHS) regions, 
combined ChromHMM and Segway predictions, conserved regions in mammals, super-
enhancers and FANTOM5 enhancers. For each of the 24 categories, a 500-bp window was 
used. Linkage disequilibrium data were provided by the LD score software, estimated from 
the EUR samples in the 1000 Genomes Project Phase 1. Enrichment per category was 
calculated by the ratio of the estimated proportion of heritability explained by the category 
over the proportion of the markers in the category.
PrediXcan and Monocyte eQTL Co-Localization analyses
We carried out a gene-based test of association of vitiligo with “imputed” expression profiles 
for 11,553 autosomal genes in whole blood using PrediXcan58. The analysis included 2,853 
cases and 37,412 controls from the combined GWAS. Association testing between 
expression estimates for each gene and affection status for vitiligo was performed by 
generalized logistic regression. P values were adjusted for the number of genes tested (n = 
11,553). NRROS, ZC3H7B, TNFRSF11A, BCL2L12, RALY, ASIP, OCA2, and TYR were 
excluded from the PrediXcan analysis due to poor prediction of gene expression in blood 
cells.
We derived expression quantitative trait loci (eQTLs) in peripheral blood monocytes from 
414 EUR subjects with paired genotyping and gene expression data66. SHAPEIT version2 
was used to pre-phase genotypes to produce best-guess haplotypes with imputation 
performed using IMPUTE2 and the 1000 Genomes Project phase I integrated variant set 
version 3 (March, 2012) as reference panel. We tested for co-localization of eQTL and 
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vitiligo GWAS autosomal association patterns as described67,68. Vitiligo susceptibility loci 
were defined by windows of robust association plus an added 100 kb buffer on both sides. 
eQTL probes were selected by choosing probes that resided within these windows. Probe 
quality annotation was performed using ReMOAT69 and all probes with an annotation of 
“bad” were removed. After removing non-autosomal loci and duplicate probe IDs, a total of 
904 probes remained. All vitiligo susceptibility loci contained at least one probe with the 
exception of the gene desert 3’ of TYR, for which the only probe that intersected the locus 
was excluded due to ReMOAT annotation of “bad”. Within each locus window, all SNPs 
were tested for association with all probes using linear regression. P values, MAF for each 
SNP and respective sample sizes were used as input to test for co- localization, 
simultaneously testing five mutually exclusive hypotheses by generating 5 corresponding 
posterior probabilities (PP):
• H0 (PP0): There is no association with either the GWAS or the eQTL.
• H1 (PP1): There is association for the GWAS only.
• H2 (PP2): There is association for the eQTL only.
• H3 (PP3): There is association for both the GWAS and the eQTL, but the 
associated variants are different for the GWAS and the eQTL.
• H4 (PP4): The associated variants are the same for both the GWAS and the 
eQTL (co-localization).
Posterior probabilities were calculated using the R package “coloc” using default settings for 
prior probabilities of association. Co-localization was assessed as per Guo et al.68; 
significant co-localization was PP3+PP4 > 0.99 and PP4:PP3 > 5, and suggestive co-
localization was PP3+PP4 > 0.95 and PP4:PP3 > 3.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Genome-wide meta-analysis results. The genome-wide distribution of −log10 (P values) 
from the Cochran-Mantel-Haenszel meta-analysis for 8,966,411 genotyped and imputed 
markers from GWAS1, GWAS2, and GWAS3 is shown across the chromosomes. The dotted 
line indicates the threshold for genome-wide significance (P < 5 × 10−8).
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Figure 2. 
Bioinformatic functional interaction network analysis of proteins encoded by all positional 
candidate genes at all confirmed and suggestive vitiligo candidate loci. As a first step, 
unsupervised functional interaction network analysis was carried out using STRING 
v10.011, considering each protein as a node and permitting ≤ 5 second-order interactions to 
maximize connectivity. Nodes that shared no edges with other nodes were then excluded 
from the network. Edge colors are per STRING: teal, interactions from curated databases; 
purple, experimentally determined interactions; green, gene neighborhood; blue, databases; 
red, gene fusions; dark blue, gene co-occurrence; pale green, text-mining; black, co-
expression; lavender, protein homology. Note that SMEK2 is an alternative name for 
PPP4R3B.
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Figure 3. 
Concordant associations for vitiligo and other autoimmune and inflammatory diseases. We 
searched the NHGRI-EBI GWAS Catalog and PubMed for associations of the 48 genome-
wide significant and 7 suggestive vitiligo susceptibility loci with other autoimmune, 
inflammatory, and immune-related disorders, and for association with normal human 
pigmentation variation. Only reported associations that achieved genome-wide significance 
(P < 5 × 10−8) are included. RA, rheumatoid arthritis; T1D, type 1 diabetes mellitus; AITD, 
autoimmune thyroid disease; SLE, systemic lupus erythematosus; IBD, inflammatory bowel 
disease; MS, multiple sclerosis; MG, myasthenia gravis; AI hepatitis, autoimmune hepatitis.
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Figure 4. 
Enrichment estimates for functional annotations. The combined CMH GWAS123 summary 
statistics were analyzed using the stratified LD score regression method utilizing the full 
baseline model51. Regulatory, yellow; protein coding, blue; intron, green. Bar height 
represents enrichment which is defined to be the proportion of SNP heritability in the 
category divided by the proportion of SNPs in that category. Error bars represent jackknife 
standard error around the enrichment. For each category, percentage of the total markers in 
the category is in parentheses. Dashed line represents a ratio of 1 (no enrichment). Asterisks 
indicate enrichment significant at P < 0.05 after Bonferroni correction for the 20 categories 
tested (the categories conserved, repressed, transcribed, and promoter flanking were 
removed and considered insufficiently specific). CTCF, CCCTC-binding factor; DGF, digital 
genomic footprint; DHS, DNase hypersensitivity site; TFBS, transcription factor binding 
site; TSS, transcriptional start site; 5’ and 3’ UTR, 5’ and 3’ untranslated regions. 
H3K4me1, H3K4me3, H3K9ac, and H3K27ac are regulatory chromatin marks56,57.
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